GeoVax Labs Inc. announced that its appeal hearing before the Nasdaq Hearings Panel regarding a delisting determination based on minimum bid price requirements is scheduled for October 13, 2026. The company received the initial delisting notice on August 27, 2026, but the pending appeal has stayed any suspension or delisting action, allowing common stock to continue trading under the symbol GOVX at least through that period. GeoVax intends to present a compliance plan to regain adherence to Nasdaq listing standards during the hearing. The company reaffirmed its strategic focus on advancing its priority program GEO-MVA toward a pivotal Phase 3 clinical trial and developing Gedeptin for oncology applications. GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on developing vaccines and immunotherapies against high-consequence infectious diseases and solid tumor cancers.

GeoVax Labs, Inc. received a Nasdaq notice of non-compliance with the $2,500,000 minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1). The company has until August 21, 2026, to submit a plan to regain compliance, with the potential for a 180-day extension if the plan is accepted. GeoVax Labs, Inc. is a biotechnology company focused on developing vaccine and immunotherapy products.